^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

Excerpt:
All those patients with tumors harboring common ALK resistance mutations, including E1129V, L1196M, C1156Y, I1171T and F1174V, had partial responses with ceritinib, while a patient with G1202R did not respond
DOI:
10.2147/DDDT.S113500